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Regulatory T cells (Tregs) play an integral role in the
adaptive immune system through suppression of self-
reactive immune responses in order to prevent autoim-
munity and maintain homeostasis. However, they are
deleterious in cancer through suppression of the anti-
tumor immune response. In fact, we show that deletion of
50% of Tregs results in normal tumor growth. Therefore, it
is advantageous to understand the role of Tregs in the
tumor microenvironment in order to create targeted can-
cer therapies. Our lab has shown that the Neuropilin-1
(Nrp1) pathway is required for Treg stability in the tumor
microenvironment, but is disposable for maintaining
immune homeostasis in the periphery, identifying it as a
prime therapeutic target.
In order to further understand the role of Nrp1-deficient
Tregs intratumorally, we constructed a competitive
environment by utilizing Foxp3, which is located on the X
chromosome, and as a result of X-inactivation, female
Foxp3Cre-YFP heterozygous mice are cellular heterozygotes.
We generated Nrp1L/LFoxp3Cre-YFP/+ heterozygous mice
comprised of 50% WT Tregs and 50% Nrp1-deficient Tregs.
Surprisingly, when given B16 melanoma, heterozygous
mice phenocopyNrp1L/LFoxp3Cre-YFP homozygous mice
(Figure 1A). This suggests that Nrp1-deficient Tregs are
playing an active role in shifting the anti-tumor
immune response by destabilizing surrounding WT
Tregs as determined by DNA methylation status
(Figure 1B). Neither WT nor Nrp1-deficient Tregs in the
tumor from Nrp1L/LFoxp3Cre-YFP/+ mice can suppress in a
standard microsuppression assay ex vivo, unlike WT Tregs
from Foxp3Cre-YFP mice. Through various co-culture
experiments, we revealed that destabilization of WT Tregs
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is possibly due to a soluble factor derived from Nrp1-
deficient Tregs. Our data revealed that Nrp1-deficient
Tregs produce large amounts of IFNg in the tumor
microenvironment. Indeed, when treated with IFNg,
WT Tregs lose suppressive capacity . In order to
uncover potential novel pathways leading to this pheno-
type, we are performing global transcript studies using
RNASeq. Overall, we have shown that Nrp1 is required
for intratumoral Treg stability, and in its absence, there
is an alteration in the tumor microenvironment, leading
to an enhanced anti-tumor immune response. These
studies uncover a novel potential target for future can-
cer immunotherapies that preserves peripheral immune
health.
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